This study is currently recruiting

Description: Learn more about MT-3-01 study, the clinical study that is assessing the efficacy and safety of leriglitazone on the progression of cerebral X-linked Adrenoleukodystrophy (cALD).

Eligibility & Criteria

IRB # : 00382750

Principal Investigator: Dr. Eric Mallack

Eligible Age Range:18 years of age and older

Gender: Male

Diagnosis: Genetic confirmation of X-ALD and have a progressive cALD

Contact Information: Jordan Goodman, Study Coordinator at or 443-923-2769.

View research flyer